Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Insights, Forecast to 2034
SGLT2 is a member of the sodium-glucose cotransporter family which are sodium-dependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney.The growing global type-2 diabetes population promotes the growth of SGLT2 drugs.
Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
Globally, Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors key manufacturers include Eli Lilly, Janssen Pharmaceuticals, Astellas, Boehringer Ingelheim, AstraZeneca, Bristol Myers Squibb and Kotobuki Pharmaceutical, etc. Eli Lilly, Janssen Pharmaceuticals, Astellas are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market and estimated to attract more attentions from industry insiders and investors.
Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors can be divided into Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/Forxiga (Dapagliflozin) and Suglat (Ipragliflozin), etc. Invokana (Canagliflozin) is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors is widely used in various fields, such as Hospital, Medical Research Institute and Other,, etc. Hospital provides greatest supports to the Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors industry development. In 2022, global % sales of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors went into Hospital filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Eli Lilly
Janssen Pharmaceuticals
Astellas
Boehringer Ingelheim
AstraZeneca
Bristol Myers Squibb
Kotobuki Pharmaceutical
Segment by Type
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Hospital
Medical Research Institute
Other
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors plant distribution, commercial date of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors introduction, etc. Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
Globally, Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors key manufacturers include Eli Lilly, Janssen Pharmaceuticals, Astellas, Boehringer Ingelheim, AstraZeneca, Bristol Myers Squibb and Kotobuki Pharmaceutical, etc. Eli Lilly, Janssen Pharmaceuticals, Astellas are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market and estimated to attract more attentions from industry insiders and investors.
Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors can be divided into Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/Forxiga (Dapagliflozin) and Suglat (Ipragliflozin), etc. Invokana (Canagliflozin) is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors is widely used in various fields, such as Hospital, Medical Research Institute and Other,, etc. Hospital provides greatest supports to the Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors industry development. In 2022, global % sales of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors went into Hospital filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Eli Lilly
Janssen Pharmaceuticals
Astellas
Boehringer Ingelheim
AstraZeneca
Bristol Myers Squibb
Kotobuki Pharmaceutical
Segment by Type
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Segment by Application
Hospital
Medical Research Institute
Other
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors plant distribution, commercial date of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors introduction, etc. Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices